Table 2. Clinical characteristic of the studied subjects.

Histology	Training group									Validation group
	No.of Patients	Age (years)			Sex(No.of Patients)		Grade (No.of Patients)			No.of Patients	Age (years)			Sex(No.of Patients)		Grade (No.of Patients)
		range	median	mean	male	female	1	2	3		range	Median	mean	male	female	1	2	3
Healthy controls	350	20–80	59	57.7	162	188				389	19–78	58	57.9	205	184
Benign lung disease										78	22–75	57	56.6	39	39
benign tumor										48	22–75	57	56.8	23	25
Lung inflammation										19	47–68	55	55.6	12	7
pulmonary tuberculosis										11	26–75	57	57.5	4	7
Lung cancer	350	27–85	60	59.6	218	132	140	169	41	411	28–87	60	59.9	267	144	181	161	69
stageI	95	27–76	61	61.1	58	37	21	47	27	123	28–87	60	59.3	71	52	29	52	42
stageII	60	40–85	59	60.3	37	33	18	39	3	76	42–82	62	51.8	51	25	31	33	12
stageIII	100	38–80	60	59.6	66	34	48	49	3	112	38–86	59	60.1	80	32	64	43	5
stageIV	95	36–78	57	57.5	57	38	53	34	8	100	35–78	59	58.7	68	32	57	33	10
NSCLC	319	27–80	60	59.6	195	124	110	168	41	371	28–87	60	59.7	235	136	141	161	69
squamous cell carcinoma	114	27–80	62	61.1	90	24	44	65	5	114	28–86	62	61.5	99	15	51	60	3
adenocarcinoma	197	33–78	59	58.9	101	96	62	100	35	247	32–87	59	58.8	128	119	84	87	76
other	8	37–69	57	56.4	4	4	4	3	1	10	38–74	62	60.3	8	2	6	4	0
SCLC	31	42–85	58	59.1	23	8	30	1	0	40	46–82	62	61.4	32	8	40	0	0